| Drug General Information |
| Drug ID |
D0R6PX
|
| Former ID |
DIB018052
|
| Drug Name |
(-)-(R)-efonidipine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
|
| Formula |
C34H38N3O7P
|
| InChI |
InChI=1S/C34H38N3O7P/c1-24-30(33(38)42-19-18-36(28-15-9-6-10-16-28)21-26-12-7-5-8-13-26)31(27-14-11-17-29(20-27)37(39)40)32(25(2)35-24)45(41)43-22-34(3,4)23-44-45/h5-17,20,31,35H,18-19,21-23H2,1-4H3/t31-/m1/s1
|
| InChIKey |
NSVFSAJIGAJDMR-WJOKGBTCSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
|
| Target and Pathway |
| Target(s) |
Voltage-dependent T-type calcium channel alpha-1G subunit |
Target Info |
Blocker (channel blocker) |
[2]
|
|---|
| Voltage-dependent L-type calcium channel subunit alpha-1C |
Target Info |
Blocker (channel blocker) |
[2]
|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Calcium signaling pathway
|
|
Circadian entrainment
|
|
Type II diabetes mellitushsa04010:MAPK signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
cAMP signaling pathway
|
|
Cardiac muscle contraction
|
|
Adrenergic signaling in cardiomyocytes
|
|
Vascular smooth muscle contraction
|
|
Long-term potentiation
|
|
Retrograde endocannabinoid signaling
|
|
Glutamatergic synapse
|
|
Cholinergic synapse
|
|
Serotonergic synapse
|
|
GABAergic synapse
|
|
Dopaminergic synapse
|
|
Insulin secretion
|
|
GnRH signaling pathway
|
|
Oxytocin signaling pathway
|
|
Type II diabetes mellitus
|
|
Alzheimer's disease
|
|
Amphetamine addiction
|
|
Hypertrophic cardiomyopathy (HCM)
|
|
Arrhythmogenic right ventricular cardiomyopathy (ARVC)
|
|
Dilated cardiomyopathy
|
|
NetPath Pathway
|
IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Endogenous cannabinoid signaling
|
|
GABA-B receptor II signaling
|
|
Nicotine pharmacodynamics pathwayP00003:Alzheimer disease-amyloid secretase pathway
|
|
Nicotinic acetylcholine receptor signaling pathway
|
|
5HT2 type receptor mediated signaling pathway
|
|
Beta1 adrenergic receptor signaling pathway
|
|
Beta2 adrenergic receptor signaling pathway
|
|
Oxytocin receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathway
|
|
Pathway Interaction Database
|
Regulation of nuclear beta catenin signaling and target gene transcription
|
|
PathWhiz Pathway
|
Muscle/Heart ContractionPW000564:Muscle/Heart Contraction
|
|
Reactome
|
NCAM1 interactionsR-HSA-400042:Adrenaline,noradrenaline inhibits insulin secretion
|
|
NCAM1 interactions
|
|
Regulation of insulin secretion
|
|
WikiPathways
|
NCAM signaling for neurite out-growth
|
|
Nicotine Activity on Chromaffin CellsWP536:Calcium Regulation in the Cardiac Cell
|
|
Arrhythmogenic Right Ventricular Cardiomyopathy
|
|
Alzheimers Disease
|
|
Integration of energy metabolism
|
|
Nicotine Activity on Chromaffin Cells
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2519). |
|---|
| REF 2 | Identification of R(-)-isomer of efonidipine as a selective blocker of T-type Ca2+ channels. Br J Pharmacol. 2004 Dec;143(8):1050-7. Epub 2004 Nov 15. |
|---|
